Implementation of RAS testing in patients with metastatic colorectal cancer in German outpatient cancer centers – data from the clinical TKK registry. 7. Juni 2015 Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Frank, M., Kopfmann, S., Jänicke, M., Marschner, N., 2015. Oncol Res Treat 38 (suppl 5)(V394), 113–114. doi:10.1159/000439070 Abstract Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany. Mustea, A., Oskay-Oezcelik, G., Wimberger, P., Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Sehouli, J., 2015. European Journal… Weiterlesen Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment – data from the prospective TKK registry. Schnell, R., Trarbach, T., Broszeit-Luft, S., Musch, R., Wetzel, N., Kopfmann, S., Jänicke, M., Marschner, N., 2015. Oncol Res Treat 38 (suppl 5)(V395), 114. doi:10.1159/000439070… Weiterlesen